Compass Therapeutics, Inc. announced as previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer. Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass? Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +0.69% | -3.95% | -6.41% |
Apr. 25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
Apr. 25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.41% | 200M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CMPX Stock
- News Compass Therapeutics, Inc.
- Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024